Lucid Diagnostics makes EsoGuard, a DNA test that screens for precancerous changes in the esophagus in people with chronic heartburn. LUCD reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 23 | BTIG | Reiterated | Buy | |
| Aug 27 | Ascendiant Capital | Target raised | Buy | |
| Jun 8 | Ascendiant Capital | Maintained | Buy |
Seasonality
How LUCD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in LUCD in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LUCD is in one of them and how their past LUCD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LUCD in an article yet. Here's the latest on the wider market.
About Lucid Diagnostics
Lucid Diagnostics is a medical diagnostics company based in New York. Its main product is EsoGuard, a DNA test that looks for precancerous changes in the esophagus, run on cell samples collected with the EsoCheck swallowable capsule device. The company targets people with chronic heartburn, also known as GERD, who are at risk of esophageal cancer, and it offers testing through its own test centers, mobile units, physician office programs and health system arrangements.
- Headquarters
- New York, NY